Pharming Group to Present at BioCapital Europe 2021
News provided by
11 Mar, 2021, 06:00 GMT
LEIDEN, The Netherlands, March 11, 2021 /PRNewswire/ Pharming Group N.V. ( Pharming or the Company ) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announces that its Chief Executive Officer, Sijmen de Vries, will present at BioCapital Europe 2021 at 10:30 CET on 11 March 2021. BioCapital Europe, organized by LSP, is Europe s premier life sciences investment conference, offering VCs and Institutional Investors unique and timely access to around 40 exciting biotech, medtech and diagnostics companies from the Benelux and Europe.
The Company s presentation will be available following the event on its website at www.pharming.com
Pharming Group reports financial results for full year 2020
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Pharming Group, in collaboration with Invitae Corporation, launches genetic testing program navigateAPDS in US and Canada
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Intravacc announces formation of Scientific Advisory Board
News provided by
Share this article
BILTHOVEN, the Netherlands, Feb. 23, 2021 /PRNewswire/
Intravacc, a world leader in translational research and development of vaccines, today announced the formation of a Scientific Advisory Board ( SAB ), chaired by Intravacc s Chief Scientific Officer Virgil Schijns and further comprising scientific leaders in the fields of vaccinology, infectious diseases and oncology. Intravacc s SAB will be consulted to help define the proper vaccine strategies and solutions to establish an impact on public health supported by convincing scientific clinical data. The SAB will also advise on the company s research strategy and approaches to optimize therapy effectiveness and added value.